Holen Sie sich die Stockscreener-App
4.58
3.17%
-0.15
Vorhandelsmarkt:
4.60
0.02
+0.44%
Schlusskurs vom Vortag:
$4.73
Offen:
$4.7
24-Stunden-Volumen:
906.64K
Relative Volume:
0.81
Marktkapitalisierung:
$877.98M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-74.39M
KGV:
-10.41
EPS:
-0.44
Netto-Cashflow:
$-78.92M
1W Leistung:
+2.46%
1M Leistung:
+4.57%
6M Leistung:
+27.58%
1J Leistung:
+15.66%
1-Tages-Spanne:
$4.57
$4.76
1-Wochen-Bereich:
$4.40
$4.945
52-Wochen-Spanne:
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Firmenname
Arbutus Biopharma Corp
Sektor
Branche
Telefon
604-419-3200
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Vergleichen Sie ABUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.58 | 906.73M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-02 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Eingeleitet | Jefferies | Hold |
| 2020-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-07-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-06 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Bestätigt | B. Riley FBR | Buy |
| 2019-10-04 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Hochstufung | Wedbush | Underperform → Neutral |
| 2018-10-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-06 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2018-03-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Bestätigt | Wedbush | Outperform |
| 2016-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
Alle ansehen
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
Is Arbutus Biopharma Corporation (I9DN) stock a buy for dividend portfoliosJuly 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
Intraday pattern recognizer results for Arbutus Biopharma CorporationEarnings Growth Summary & Entry Point Strategy Guides - newser.com
Quantitative breakdown of Arbutus Biopharma Corporation recent move2025 Earnings Surprises & Daily Technical Stock Forecast Reports - newser.com
Predicting Arbutus Biopharma Corporation trend using moving averagesEarnings Summary Report & Entry Point Confirmation Alerts - newser.com
Why Arbutus Biopharma Corporation (I9DN) stock stays undervalued2025 Fundamental Recap & Daily Stock Momentum Reports - newser.com
Is this a good reentry point in Arbutus Biopharma CorporationChart Signals & High Win Rate Trade Alerts - newser.com
Will Arbutus Biopharma Corporation stock recover faster than marketJuly 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
Signal strength of Arbutus Biopharma Corporation stock in tech scannersWeekly Trend Recap & Technical Analysis for Trade Confirmation - newser.com
Can Arbutus Biopharma Corporation stock deliver surprise earnings beat2025 Trading Recap & Reliable Breakout Forecasts - newser.com
Arbutus Biopharma Corporation (ABUS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Can Arbutus Biopharma Corporation stock continue upward trend2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - newser.com
Custom strategy builders for tracking Arbutus Biopharma CorporationGDP Growth & Daily Entry Point Trade Alerts - newser.com
Arbutus Biopharma (ABUS) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Can Arbutus Biopharma Corporation stock sustain revenue growthForecast Cut & Advanced Technical Analysis Signals - newser.com
Arbutus Biopharma Corporation stock trend outlook and recovery pathPortfolio Gains Report & Daily Growth Stock Investment Tips - newser.com
Can Arbutus Biopharma Corporation stock resist market sell offsShort Setup & Reliable Breakout Stock Forecasts - Fundação Cultural do Pará
Aug Mood: Can Arbutus Biopharma Corporation stock continue upward trendRate Cut & Weekly Watchlist of Top Performers - fcp.pa.gov.br
Is it time to cut losses on Arbutus Biopharma CorporationJuly 2025 Movers & Daily Risk Controlled Trade Plans - newser.com
What technical signals suggest for Arbutus Biopharma Corporation stockEarnings Growth Report & High Accuracy Buy Signal Tips - fcp.pa.gov.br
Will Arbutus Biopharma Corporation (I9DN) stock see insider accumulationShort Setup & Accurate Entry/Exit Alerts - newser.com
Arbutus Biopharma’s (ABUS) Sell (D-) Rating Reiterated at Weiss Ratings - Defense World
How Arbutus Biopharma Corporation (I9DN) stock trades under stagflationMarket Activity Summary & Free High Return Stock Watch Alerts - newser.com
What to do if you’re stuck in Arbutus Biopharma CorporationQuarterly Trade Review & Capital Efficient Trade Techniques - newser.com
Published on: 2025-10-26 22:31:52 - newser.com
Can Arbutus Biopharma Corporation stock attract ESG capital inflowsWeekly Trade Report & Weekly Breakout Opportunity Watchlist - newser.com
Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):